Plain-English translation of NCT05406635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether blood tests can replace regular heart imaging scans in people being treated for HER2-positive breast cancer with trastuzumab and/or pertuzumab. These medications are very effective against this type of breast cancer, but they can sometimes weaken the heart muscle. Right now, doctors monitor heart health using imaging scans (like echocardiograms), which are time-consuming and expose you to radiation—this study asks whether simpler blood tests could do the same job.
The medications used to treat HER2-positive breast cancer can affect heart function, so doctors need to monitor patients carefully. Current monitoring requires frequent heart imaging scans, which are resource-intensive and involve radiation exposure. This trial exists to see if blood biomarkers—special proteins that signal heart stress—could be a simpler, safer alternative.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will receive standard heart monitoring with imaging scans (ultrasound or nuclear scans) at weeks 0, 9, 18, 30, and 48 of treatment, plus blood tests that doctors won't look at until the study ends. The other group will have heart monitoring guided by blood tests at the same time points, with imaging scans performed but hidden from your treatment team. Either way, you'll have regular check-ins throughout your cancer treatment to ensure your heart stays safe.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Denmark